Obstetric and neonatal outcomes in pregnancies from a dedicated cystic fibrosis-maternal health service: a retrospective study
Author(s)
Type
Journal Article
Abstract
Objective
A comprehensive review of maternal, obstetric and neonatal outcomes in pregnancies in females with cystic fibrosis (fwCF) following the introduction of Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy in a novel, dedicated CF-Maternal Health service.
Design
Retrospective data review from a CF-Maternal Health service between September 2020 and February 2025.
Setting
A large adult-CF service in London, UK.
Population or Sample
Pregnant fwCF attending the Royal Brompton Hospital CF Service.
Methods
Review of CF-Maternal Health service data.
Main Outcome Measures
Maternal, obstetric and neonatal outcomes.
Results
Fifty-three fwCF completed 67 pregnancies, with 69 infants born. There were no stillbirths, neonatal or maternal deaths. ETI-therapy was reported in 81% of pregnancies. In fwCF without CF-Diabetes, 57% developed gestational diabetes. Hospital admission to treat an infective pulmonary exacerbation was required in 31% of pregnancies. Forty-five percent of pregnancies delivered vaginally; 78% of babies were born at term. A major congenital abnormality was diagnosed in 4% of infants. Baseline lung-function correlated positively with birth-weight and gestation at birth.
Conclusions
FwCF have improved maternal, obstetric and neonatal outcomes since the introduction of ETI-therapy, within a dedicated CF-Maternal Health service.
A comprehensive review of maternal, obstetric and neonatal outcomes in pregnancies in females with cystic fibrosis (fwCF) following the introduction of Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy in a novel, dedicated CF-Maternal Health service.
Design
Retrospective data review from a CF-Maternal Health service between September 2020 and February 2025.
Setting
A large adult-CF service in London, UK.
Population or Sample
Pregnant fwCF attending the Royal Brompton Hospital CF Service.
Methods
Review of CF-Maternal Health service data.
Main Outcome Measures
Maternal, obstetric and neonatal outcomes.
Results
Fifty-three fwCF completed 67 pregnancies, with 69 infants born. There were no stillbirths, neonatal or maternal deaths. ETI-therapy was reported in 81% of pregnancies. In fwCF without CF-Diabetes, 57% developed gestational diabetes. Hospital admission to treat an infective pulmonary exacerbation was required in 31% of pregnancies. Forty-five percent of pregnancies delivered vaginally; 78% of babies were born at term. A major congenital abnormality was diagnosed in 4% of infants. Baseline lung-function correlated positively with birth-weight and gestation at birth.
Conclusions
FwCF have improved maternal, obstetric and neonatal outcomes since the introduction of ETI-therapy, within a dedicated CF-Maternal Health service.
Date Issued
2026-03-01
Date Acceptance
2025-10-23
Citation
BJOG: An International Journal of Obstetrics and Gynaecology, 2026, 133 (4)
ISSN
1470-0328
Publisher
Wiley
Journal / Book Title
BJOG: An International Journal of Obstetrics and Gynaecology
Volume
133
Issue
4
Copyright Statement
© 2025 The Author(s). BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/41208508
Subjects
CFTR-modulators
cystic fibrosis
Elexacaftor/Tezacaftor/Ivacaftor
ELEXACAFTOR/TEZACAFTOR/IVACAFTOR
FERTILITY
GUIDELINES
Life Sciences & Biomedicine
maternal medicine
Obstetrics & Gynecology
PEOPLE
pregnancy
Science & Technology
WOMEN
Publication Status
Published
Coverage Spatial
England
Date Publish Online
2025-11-10